SCHEMBL3109672

SCHEMBL3109672

COC(=O)c1ccc(OC2CCC(=O)CC2)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.50
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
PDE4A P27815 4/20 0.44
PDE4B Q07343 4/20 0.44
PDE4C Q08493 4/20 0.44
PDE4D Q08499 4/20 0.44
ALDH1A1 P00352 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
CYP3A4 P08684 1/20 0.42
ESRRA P11474 1/20 0.42
TAS1R3 Q7RTX0 2/20 0.42
TAS1R1 Q7RTX1 2/20 0.42
IP6K1 Q92551 1/20 0.41
EPHX2 P34913 1/20 0.41
BCL6 P41182 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16544907 0.90 RORC (0.59) RORCMAPTMEN1NPC1RAB9A
SCHEMBL8505957 0.88 PDE4D (0.55) RORCPDE4APDE4BPDE4CPDE4D
SCHEMBL8503889 0.86 PDE4D (0.54) RORCPDE4APDE4BPDE4CPDE4D
SCHEMBL2215999 0.84 UTS2R (0.50) RORCMAPTMEN1NPC1RAB9A
SCHEMBL2216622 0.81 EPHX2 (0.53) RORCMAPTMEN1NPC1RAB9A
SCHEMBL13158234 0.79 RORC (0.48) RORCMAPTMEN1NPC1RAB9A
SCHEMBL3115388 0.79 CYP3A4 (0.43) RORCMAPTMEN1NPC1RAB9A
SCHEMBL7659739 0.77 EPHX2 (0.52) MAPTMEN1RAB9AKMT2AALDH1A1
SCHEMBL18031253 0.77 MAPT (0.53) MAPTKMT2APDE4APDE4BPDE4C
SCHEMBL16448714 0.77 SCN9A (0.54)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2010-09-30 US disclosed
EP-2141994-A1 MULTI-RING COMPOUNDS AND USES THEREOF Avalon Pharmaceuticals (US) 2010-01-13 EP disclosed
WO-2008133975-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2008-11-06 WO disclosed
WO-2008133975-A1 MULTI-RING COMPOUNDS AND USES THEREOF AVALON PHARMACEUTICALS (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249111-A1 MULTI-RING COMPOUNDS AND USES THEREOF TP53, BCOR, HPGDS RORC 898/4885MAPT 4855/4885MEN1 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.